You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The appellate court's decision deals a blow to a 2017 Columbia University lawsuit that alleged Illumina infringed one of the invalidated patents.
The cancer therapy developer has asked a US federal court to declare that its Illuminox platform does not infringe Illumina's trademarks.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.